Floatz logo

Fluciclovine

Prostatic Neoplasms, Castration-Resistant

VA Greater Los Angeles Healthcare SystemradiopharmaceuticalPhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the Prostatic Neoplasms, Castration-Resistant cohort.

Asset / SponsorPhaseRating
RADIUM RA-223
University of California, San Francisco
Phase 4BB
Atezolizumab
Cancer Research UK
Phase 3BB
tqb3616
West China Hospital
Phase 2CCC
Jnj-809
Janssen Research & Development, LLC
Phase 2CCC
Quemliclustat
Arcus Biosciences, Inc.
Phase 1/2CCC

View all 29 →

Same molecule, other indications

Fluciclovine is also rated in:

metastatic prostate carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
prostate cancerDormant
BB
Indicative ·
71 / 100
View asset →
prostate carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →